|
|
Post by kite on Mar 1, 2021 6:11:50 GMT -5
|
|
|
|
Post by Clement on Mar 1, 2021 8:59:39 GMT -5
From slide 8, UTHR says, " If approved for PH-ILD, we expect to double the number of Tyvaso patients within ~18 months of launch." From the 10-K, net Tyvaso sales for 2020 were 483.3M. So, I'm estimating an annual rate of about $966M of Tyvaso and Tyvaso DPI by the end of 2022. How much of that will be Tyvaso DPI? |
|
|
|
Post by boca1girl on Mar 2, 2021 20:50:41 GMT -5
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 41st annual Cowen Health Care Conference.
The session will take place virtually on Wednesday March 3, 2021, from 10:20 a.m. to 10:50 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website
|
|
|
|
Post by kite on Mar 9, 2021 13:14:31 GMT -5
United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 9, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Oppenheimer 31st Annual Healthcare Conference. The session will take place virtually on Tuesday, March 16, 2021, from 3:10 p.m. to 3:40 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days. |
|
|
|
Post by kite on Mar 24, 2021 10:21:47 GMT -5
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Corporation-To-Present-At-The-10th-Annual-J.P.-Morgan-Napa-Valley-Forum/default.aspxSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Gil Golden, Executive Vice President and Chief Medical Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 10th Annual J.P. Morgan Napa Valley Forum. The session will take place virtually on Wednesday, March 31, 2021, from 12:00 p.m. to 12:45 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 30 days. About United Therapeutics United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term. Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. Forward-looking Statements Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our ability to create value and sustain our success in the long-term, as well as our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of March 24, 2021 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason. |
|
|
|
Post by boca1girl on Mar 24, 2021 11:35:24 GMT -5
I signed up to listen in but couldn’t log in. The error said not yet started, check back in 7 days.
Hopefully a replay will be posted.
|
|
|
|
Post by kite on Mar 24, 2021 12:21:27 GMT -5
I signed up to listen in but couldn’t log in. The error said not yet started, check back in 7 days. Hopefully a replay will be posted. The session will take place virtually on Wednesday, March 31, 2021, from 12:00 p.m. to 12:45 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 30 days. |
|
|
|
Post by mytakeonit on Mar 24, 2021 14:13:17 GMT -5
Come on kite ... give the girl a break. She had too much wine with lobster last night ... but, after the hang over she'll be fine before next week.
But, that's mytakeonit
|
|
|
|
Post by boca1girl on Mar 24, 2021 19:55:20 GMT -5
I signed up to listen in but couldn’t log in. The error said not yet started, check back in 7 days. Hopefully a replay will be posted. The session will take place virtually on Wednesday, March 31, 2021, from 12:00 p.m. to 12:45 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 30 days. Ops. I saw the date of the article and that’s what registered. Hopefully they have better news to report next week. |
|
|
|
Post by joshuabohinc on Apr 7, 2021 15:31:01 GMT -5
|
|
|
|
Post by Clement on Apr 8, 2021 14:23:12 GMT -5
up 4.7% right now. on what?
|
|
|
|
Post by wyattdog on Apr 8, 2021 15:13:36 GMT -5
** Brokerage J.P.Morgan is optimistic about the market opportunity for United Therapeutics Corp's drug Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD) ** Raises PT to $212 from $185, implying an upside of about 11% to UTHR's last close ** The U.S. FDA earlier in the month approved use of the drug, which was already indicated for pulmonary arterial hypertension, to treat PH-ILD [nL4N2LU3C7] ** Brokerage says its survey showed most U.S. physicians found the drug's late-stage data promising and thought the product was safe and effective ** Within first year of approval, physicians anticipate putting >25% of PH-ILD patients on Tyvaso and expect this number to grow to >40% over the next five years - brokerage ** Brokerage Jefferies hosted a call with a pulmonary hypertension specialist, who expects Tyvaso use to at least double over the next year after expanded label; brokerage raises PT to $215 to $230 ** UTHR up 2.6% at $195.6; stock had risen about 26% YTD up to last close (Reporting by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters
|
|
|
|
Post by kite on Jun 23, 2021 6:43:29 GMT -5
FORM 8-K
Item 1.02. Termination of a Material Definitive Agreement.
On June 22, 2021, United Therapeutics Corporation (the “Company”) and Medtronic, Inc. (“Medtronic”) agreed to discontinue further efforts to develop and commercialize the Implantable System for Remodulin® (“ISR”). By way of background, the ISR has been developed over the past 12 years in collaboration with Medtronic to deliver Remodulin (treprostinil) Injection for patients with pulmonary arterial hypertension (“PAH”) via an implantable system developed by Medtronic. On February 25, 2019, Medtronic and the Company entered into a Commercialization Agreement governing the parties’ collaboration to commercialize the ISR in the United States (the “Commercialization Agreement”). Despite approval by the U.S. Food and Drug Administration (“FDA”) of Medtronic’s premarket approval application (“PMA”) for the ISR in December 2017, commercial launch of the product required Medtronic, as the applicant, to satisfy certain conditions to its PMA approval. Based on the evolution of treatment options and paradigms in PAH over the past few years, and the anticipated efforts required to satisfy the FDA’s conditions of approval, the Company and Medtronic have decided to discontinue further efforts to develop and commercialize the ISR. The Company and Medtronic plan to work together on a mutually-agreed approach to wind-down the development program, and to support patients already enrolled in clinical studies of the ISR, at the Company’s sole expense. Effective June 22, 2021, the parties mutually agreed to terminate the Commercialization Agreement. There were no penalties associated with the termination of the Commercialization Agreement.
Forward-looking Statements
Statements included in this Current Report on Form 8-K that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding plans to wind-down the development of the ISR and to support patients enrolled in clinical studies of the ISR. These forward-looking statements are subject to certain risks and uncertainties, such as those described in the Company’s periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. Such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in UT’s periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. UT claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The Company is providing this information as of June 23, 2021, and assumes no obligation to update or revise the information contained in this Current Report on Form 8-K whether as a result of new information, future events or any other reason.
REMODULIN is a registered trademark of United Therapeutics Corporation.
|
|
|
|
Post by Clement on Jul 28, 2021 7:23:33 GMT -5
|
|
|
|
Post by uvula on Jul 29, 2021 8:07:06 GMT -5
This singer is not affiliated with uthr, but is an example of why the work uthr is doing is so important. I just saw a news segment about her and PAH. www.chloetemtchine.com/ |
|
